Valance

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Valance

Property Description
Active ingredient Divalproex Sodium (Valproic Acid derivative)
Form Oral Tablets (Extended-Release/Delayed-Release)
Pharmacological class Anticonvulsant/Anti-epileptic Drug (AED) and Mood Stabilizer
Common use Seizure control, acute mania in Bipolar Disorder, and Migraine prevention
Origin Synthetic compound

Valance (active ingredient: Divalproex Sodium) is a prescription medication often supplied in a delayed- or extended-release oral tablet formulation. It is classified as both an Anticonvulsant (anti-epileptic drug) and a Mood Stabilizer. This dual classification highlights its ability to regulate overactive nerve signals in the central nervous system.

Core Therapeutic Uses

Valance is a well-established treatment for three primary conditions:

  1. Epilepsy: Its primary role is to control and prevent various types of seizures by stabilizing abnormal electrical activity in the brain.
  2. Bipolar Disorder: It is a core medication used to manage and reduce the intensity of acute manic or mixed episodes, helping to stabilize extreme mood swings in patients with bipolar disorder.
  3. Migraine Prophylaxis: It is commonly prescribed as a preventive measure for individuals who experience frequent and debilitating migraine headaches. This preventative use is clinically recognized in neurological medicine.

As a synthetic compound, Valance's established track record means it is often considered a first-line treatment option in appropriate clinical settings. Its formulation as an extended-release tablet is a key feature, designed to provide a steady absorption of the active ingredient, which helps maintain stable blood concentrations and neurological balance over a 24-hour period.

Regulatory References

  1. NIH DailyMed Monograph

What side effects are possible with Valance?

Possible Side Effects and Safety Information

The safety profile of Valance (Divalproex Sodium) is defined by official government regulatory documents, which classify adverse reactions by frequency and the body system affected. These regulatory classifications establish a clear structure for understanding potential risks.


Frequency and System-Organ Classes

Adverse reactions are officially grouped by their reported incidence and the system-organ class (SOC) involved. Effects like nausea, tremor, somnolence, headache, and weight gain are frequently documented, often categorized as Very Common or Common. Reactions affect several SOCs, including Gastrointestinal disorders and Nervous system disorders.

Classification Examples of Documented Effects
Common Nausea, Vomiting, Tremor, Somnolence, Alopecia, Weight gain
SOC Focus Gastrointestinal, Nervous System, Hepato-biliary

Serious Adverse Reactions and Constraints

The official label highlights potentially life-threatening risks, including Hepatotoxicity (severe liver failure), Pancreatitis, and an increased risk of Suicidal Ideation or Behavior. The medicine is contraindicated in patients with severe hepatic disease, certain mitochondrial disorders, and urea cycle disorders.

Specific Population-Specific Safety Considerations apply to the drug's use. It is associated with a significant risk of birth defects and neurodevelopmental disorders when used during pregnancy; therefore, its use in women of childbearing potential is highly restricted, particularly for migraine prevention. Certain effects, such as gastrointestinal issues, may be more common at the start of treatment or associated with dose escalation.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Divalproex Sodium is officially documented to present primarily with central nervous system depression. Manifestations may range from profound somnolence and lethargy to a severe loss of consciousness that progresses to deep coma. Other documented clinical signs include generalized seizures, an irregular heartbeat, and systemic effects such as hypothermia and low blood pressure. Metabolic abnormalities like hyperammonemia and metabolic acidosis are also cited in official reports.

The most serious outcomes described in regulatory documents include respiratory depression and the delayed potential for cerebral edema (brain swelling).

Required Emergency Action

The official guidance mandates that any individual suspected of an overdose, especially if exhibiting signs like coma, seizures, or respiratory distress, must seek immediate medical attention. Even for asymptomatic individuals, a large acute ingestion requires referral to an emergency department for evaluation.

Management is focused on symptomatic and supportive treatment, as regulatory information states that no specific antidote is known. Documented supportive procedures include the use of activated charcoal for decontamination and, in severe cases, procedures such as hemodialysis to enhance drug elimination. Specific population notes caution that somnolence in elderly patients may be an increased risk.

Therapeutic Uses of Valance

What Valance Treats: Main Uses and Benefits

Valance is commonly used in several therapeutic domains, contributing supportive relief for conditions associated with symptoms related to heightened neurological or emotional activity. Its applications cover a range of episodic and recurrent conditions.

The medication is relevant for easing distressing manifestations across three main indication areas: managing recurrent seizure disorders, stabilization of acute manic or mixed episodes in bipolar disorder, and prophylaxis for frequent migraine headaches. It is often used during phases when symptoms become more noticeable, providing support that helps ease the overall symptom burden.

“The strategic use of this medication may assist with maintaining functional stability and day-to-day comfort during symptomatic periods.”

The use of Valance is relevant for easing symptoms of increased neurological activity to help manage disruptive seizure activity and contributes to easing the symptom load during manic episodes. For recurrent headaches, it is used as a long-term measure to help reduce the frequency and intensity of attacks.


Quick Fact: Relief for Episodic Symptoms Valance is relevant for easing symptoms that interfere with daily functioning and is applied in clinical settings that involve acute or unstable symptom patterns, such as during manic crises or frequent, recurrent seizures.

Eligibility and Restrictions for Use

The eligibility for using Valance (Divalproex Sodium) is strictly defined by regulatory authorities based on metabolic status, organ function, and reproductive health.

Absolute Contraindications (Must Not Use)

Valance is contraindicated and must not be used by patients with Hepatic disease or significant hepatic dysfunction, known Urea Cycle Disorders (UCDs), or known mitochondrial disorders caused by POLG gene mutations. Additionally, the drug is contraindicated in patients with Porphyria or known hypersensitivity to its components.

Age and Reproductive Restrictions

Age eligibility is risk-dependent:

Age Group Official Regulatory Status
Children Under 2 Years Use requires extreme caution due to high risk of fatal hepatotoxicity.
Under 18 Years (Mania/Migraine) Safety and effectiveness not established.
Older Adults (Geriatric) Use is permitted but requires caution and monitoring.

Valance is contraindicated for migraine prophylaxis in pregnant women and in women of childbearing potential not using effective contraception. Use in women of childbearing potential for other indications is severely restricted unless other medications have failed.

What should I know about interactions with other medicines?

Valance (Divalproex Sodium) interacts with numerous substances primarily by altering metabolic processes, which can affect the plasma concentration of Valance or other co-administered medicines. The interaction profile is structured around formal restrictions and pharmacokinetic changes as documented in official regulatory labeling.

Interactions Affecting Valance Concentration (Exposure-Modification)

  • Carbapenem Antibiotics: Co-administration with Carbapenem-class agents (e.g., Meropenem, Ertapenem) is formally not recommended due to a rapid and substantial decrease in valproate plasma concentrations, which risks loss of therapeutic effect.
  • Enzyme Inducers/Inhibitors: Hepatic enzyme-inducing medicines (e.g., Phenytoin, Carbamazepine) increase Valance clearance, which may result in decreased Valance plasma levels. Conversely, enzyme inhibitors (e.g., Felbamate) can decrease clearance, potentially increasing Valance exposure. Monitoring of valproate concentrations is required when these agents are introduced or withdrawn.
  • Salicylates/Contraceptives: Aspirin (Acetylsalicylic Acid) is documented to increase valproic acid levels through plasma protein binding competition. Estrogen-containing hormonal contraceptives may decrease Valance plasma concentrations.

Valance Effect on Other Medicines (Metabolic Burden)

  • Valance can inhibit the metabolism of certain co-administered medicinal products, leading to increased plasma concentrations of agents such as Lamotrigine and Phenobarbital, thereby increasing their exposure.

Pharmacodynamic and Substance Interactions

  • CNS Depressants: Valance may potentiate the sedative effect of other Central Nervous System depressants, and alcohol intake is not recommended due to this additive effect. Co-administration with Topiramate is associated with a risk of hyperammonemia.

Population-Specific Restrictions

  • Valproate is formally contraindicated for migraine prophylaxis in women who are pregnant or of childbearing potential not using effective contraception. The drug is also contraindicated in patients with significant hepatic dysfunction, a condition which decreases Valance clearance.

Mechanism of Action

The action of Valance (Valproic Acid) is defined by its ability to stabilize the central nervous system through a combination of three distinct, simultaneous actions on key regulatory pathways.

Modulating Neuronal Excitability at the Membrane

Valproic Acid directly modulates neuronal function by interacting with voltage-gated ion channels—specifically blocking Na^+ channels and Ca^2+ channels—which are critical for generating and propagating electrical signals. This mechanism physically raises the threshold for nerve cell firing, thereby limiting the ability of neural networks to generate or sustain the rapid, synchronized electrical activity that drives excessive signaling.

️ Enhancing Endogenous Inhibitory Neurotransmission

The drug also works to strengthen the primary inhibitory pathway by increasing the functional availability of the neurotransmitter GABA. It achieves this by simultaneously inhibiting the enzyme that breaks down GABA (GABA-T) and stimulating the enzyme that synthesizes it. This dual modulation enhances the functional presence of GABA in the synapse, promoting increased inhibitory tone and resulting in a reduction of overall neuronal excitability throughout the CNS.

️ Modulating Gene Expression for Long-Term Neuronal Resilience

A slower-onset action involves epigenetic modulation through the inhibition of Histone Deacetylase (HDAC) enzymes within the cell nucleus. This mechanism alters the transcription of genes related to neuronal function and plasticity. This domain is crucial for the gradual and sustained adjustment of neuronal vulnerability, contributing to the long-term modulation of network activity over time.

Dosage and Administration Information

How Valance is Used: General Administration Guidelines

Valance (Divalproex Sodium) is approved exclusively for oral administration in the form of Delayed-Release (DR) or Extended-Release (ER) tablets. The administration protocol is defined by the specific condition being addressed and the formulation used, ensuring stable exposure to the active ingredient.


Administration and Dosing Patterns

The dosage is initiated at specific levels and is subsequently adjusted according to established titration schedules. The Extended-Release (ER) tablet is designed for once-daily intake, while the Delayed-Release (DR) tablet is generally administered in divided doses throughout the day, particularly when the daily total exceeds 250 mg.

For Epilepsy and Acute Mania, the dosage begins at 10 to 25 mg/kg/day and can be gradually or rapidly increased, with a total daily dose not to exceed 60 mg/kg/day. For Migraine Prophylaxis, the dose starts at 500 mg once daily (ER form) and may be increased up to a maximum of 1,000 mg/day.

Special Use Instructions:

Administration Constraint Standard Requirement
Tablet Integrity Tablets must be swallowed whole and must not be crushed or chewed to maintain the integrity of the controlled-release mechanism.
Intake Context Administration may occur with food if the patient experiences gastrointestinal irritation.
Dose Modification A reduced starting dose and slower titration are specified for older adults; adjustments are also required for patients with hepatic or renal impairment.

Therapy for seizure disorders is generally viewed as a long-term strategy, and discontinuation typically requires a gradual tapering of the dosage to mitigate procedural risk.

Recent Clinical Evidence

Research evidence / Overview of Studies for Valance

The following overview describes the official research that has been conducted on Valance (Divalproex Sodium), focusing on the types of studies available and the research areas they examined.


Evidence for Use in Acute Mania and Bipolar Disorder

The clinical evaluation of Valance for acute manic and mixed episodes is based primarily on short-term randomized controlled trials (RCTs). These studies were used in research exploring how outcomes capturing phases of heightened symptom activity change over a short, defined time interval. Researchers focused on studies conducted during periods of increased symptom activity, typically involving adult patients who were hospitalized for acute episodes.

In these trials, researchers primarily measured the severity of manic symptoms using standardized rating scales. Studies monitored changes related to functional imbalance and reported measurements showing how symptoms changed in the observed populations during the study period.

A key limitation of this research is its short-term focus. Consequently, long-term effects are not fully established, and there is limited information for long-term outcomes regarding the prevention of future mood episodes.


Evidence for Use in Epilepsy (Seizure Control)

Valance was extensively evaluated in multiple studies for its role in controlling various types of seizures. This research foundation includes numerous randomized controlled trials and observational settings evaluating daily-life functioning over long periods.

In these studies, research examined outcomes describing episodic or acute changes, such as the frequency of different seizure events. Researchers monitored the time between seizure episodes. The data show patterns related to how seizures were monitored in adults and in pediatric patients over defined time intervals, contributing to the broader evidence landscape for conditions involving periods of heightened symptoms.

Research has explored its role as both a single treatment (monotherapy) and as an addition to existing medication (adjunctive therapy) within the overall body of evidence.


What Research Gaps and Uncertainties Remain

While a substantial research base exists, the evidence quality varies across studies, and several research limitations have been identified. For certain uses, long-term controlled data for the maintenance phase and for the extended-duration effectiveness are not fully established.

Subgroup findings are uncertain for specific populations, including the full spectrum of children and adolescents, where data for certain groups remain insufficient. The results apply only to the populations studied in the main regulatory trials.

Frequently Asked Questions (FAQ)

Common questions about Valance (FAQ)


Q: How quickly should I expect to feel the effects of Valance?

A: According to official product information, the dosage for conditions like mania is often increased rapidly to achieve a therapeutic level. For epilepsy, dosage is commonly adjusted weekly. This means that while some effects may be noted after initial doses, reaching the optimal clinical effect is often a process that happens gradually over days to a few weeks, depending on the condition being treated.


Q: Does Valance start working right away or does it build up over time?

A: Studies on Valance's mechanism of action show it has both immediate effects and slower, longer-term actions that involve the modulation of gene expression. Because of this, and the need for gradual dose adjustments, achieving a stable, effective concentration usually requires a period of build-up over time. This process helps achieve a stable therapeutic level and sustained effect.


Q: What's the difference between Valance and other common treatments for this condition?

A: Valance has a unique triple mechanism of action compared to many other treatments. It works by blocking electrical signals in nerve channels, increasing the availability of the calming neurotransmitter GABA, and affecting long-term nerve cell resilience. These distinct actions are related to its specific safety profile and drug interaction patterns, such as its interaction with certain antibiotics.


Q: Do the side effects of Valance usually go away after the first few days?

A: Official information indicates that some common, mild side effects, such as gastrointestinal upset or drowsiness, may be more prominent when treatment begins or when the dose is being increased. While many milder effects often lessen or subside with continued use, patients should be aware that some serious effects, though rare, have typically occurred during the first six months of treatment.


Q: Is it normal to feel a little dizzy when first starting Valance?

A: Yes, dizziness is listed in the drug's safety information as one of the most commonly reported adverse reactions during clinical trials. Feeling dizzy, particularly when you first start taking the medication, is a known and frequently reported effect for many patients.


Q: Can Valance cause difficulty sleeping or insomnia?

A: Yes, although drowsiness (somnolence) is one of the most common side effects, insomnia (difficulty sleeping) is also specifically listed as a possible adverse reaction in the drug's safety information.


Q: Can taking Valance affect the results of blood tests?

A: Yes, Valance is known to produce false positive results when testing for ketones in the urine. Regulatory information indicates it may also alter the results of certain thyroid function tests. Additionally, because the medication can affect the blood's clotting ability, monitoring of platelet counts and coagulation tests may be required.


Q: Is Valance used for both short-term problems and long-term management?

A: Yes, Valance is officially indicated for both acute (short-term) and long-term management. For instance, it is used for the acute treatment of manic episodes, and it is also indicated for the long-term control of seizures and for the preventive treatment of migraines.


Q: What happens if I miss a dose of Valance?

A: The official advice states that if a dose is missed, it should generally be taken as soon as possible. However, if it is almost time for the next scheduled dose, the advice is to skip the missed one entirely. The advice is to never take a double dose to compensate for a single missed dose.


Q: Are there any known long-term effects of taking Valance for an extended period?

A: The official product labeling identifies several potentially life-threatening risks, including severe liver failure (hepatotoxicity), especially in certain high-risk individuals. The long-term effects beyond the studied timeframes are an ongoing area of evaluation.


Q: Does Valance have a risk of dependence or withdrawal symptoms?

A: Valance is not typically associated with dependence. However, regulatory labeling warns against suddenly stopping the medication, as abrupt discontinuation can increase the possibility of worsened seizure frequency. Any changes to the dosage or discontinuation require the oversight of a healthcare professional.


Q: Can Valance cause stomach upset or nausea?

A: Yes, according to clinical trial data, nausea, vomiting, and abdominal pain are among the most frequently reported side effects. The official labeling permits administration with food, which may help reduce this kind of gastrointestinal upset.


Q: What are the signs that Valance is actually working for my condition?

A: The therapeutic effect is often characterized by a measured improvement in symptoms related to the specific condition. This includes a reduction in the frequency of seizures, a decrease in the intensity of manic symptoms, or a decrease in the frequency of migraine headaches.


Q: Is it true that Valance can cause changes in mood?

A: Yes, the official labeling for Valance indicates that like other similar medications, it may carry an increased risk of suicidal thoughts or behavior. Other adverse reactions related to mood, such as depression, emotional lability, and nervousness, have also been reported.


Q: What is the consensus in the medical community about the efficacy of Valance?

A: Valance is an FDA-approved and widely used treatment. Its efficacy for treating acute mania, various seizure types, and preventing migraines is supported by multiple controlled clinical trials that established its use for these core indications.


Q: What's the typical reason people stop taking Valance?

A: The official data show that discontinuation in clinical studies is frequently linked to common adverse reactions such as nausea, vomiting, drowsiness, and tremor. Serious adverse events like pancreatitis or liver toxicity have also been factors.


Q: Are there specific times of day that are best for taking Valance?

A: Valance is available in different formulations that affect when it is taken. The Extended-Release (ER) form is generally intended for once-daily use, while the Delayed-Release (DR) form is often prescribed to be taken in divided doses throughout the day.


Q: Can Valance affect my ability to drive or operate machinery?

A: Yes, official warnings advise that Valance can cause drowsiness (somnolence) and other symptoms of Central Nervous System (CNS) depression. Regulatory warnings advise caution regarding activities that require mental alertness, such as driving or operating heavy machinery.


Q: Why is Valance prescribed in different strengths for different patients?

A: Dosing for Valance is highly individualized to fit each patient’s needs. The strength prescribed is determined based on factors like the patient’s body weight and the specific condition being treated (such as mania versus migraine), all with the goal of achieving and maintaining a stable therapeutic level in the blood.


Q: What if I accidentally take two doses of Valance close together?

A: Taking too much Valance, or an overdosage, is a serious medical event that can result in symptoms such as profound drowsiness, coma, and heart block. Official safety information notes that overdosage is a serious event that requires immediate medical attention.

How should Valance be stored and disposed of?

How to Store and Dispose of Valance

Official regulatory guidelines strictly define the storage and disposal requirements for Valance (Divalproex Sodium/Valproic Acid) to maintain its stability and ensure public safety.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, typically below 30, C (86, F).
Protection The product must be protected from both light and moisture.
Container Keep the medicine in its original container with the lid tightly closed, and keep it out of the sight and reach of children.
Prohibited Do not freeze the medicine. Do not store it above the maximum prescribed temperature.

Disposal Instructions

Unused or expired Valance must be disposed of properly. The preferred method is to return the medicine to an authorized drug take-back program or a collection site, such as those found at pharmacies or police stations. If a take-back program is unavailable, official guidance recommends mixing the medicine with an undesirable substance (like dirt or coffee grounds) and sealing it in a container before placing it in the household trash. Do not flush the medication down the toilet or sink unless specifically instructed by governmental disposal lists.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Valance found in:

A-Z Index: